Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

The Food and Drug Administration’s (FDA) approval of the first blood test to aid in the diagnosis of Alzheimer’s disease ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...

Wall Street's major averages plummeted on Friday after Israel and Iran traded missile strikes and stoked concerns of an ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly and Company (NYSE:LLY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from ...

Eli Lilly and Company (NYSE: LLY) is one of the 17 stocks that Jim Cramer commented on. Cramer showed a positive sentiment ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Sarah Strauss. Bob Jones University — Oronoco: Abigail Graham. Cedarville University —: Johanna Trondson. Central Lakes College —: Johnny Tong. Concordia University —: Hope Nelson; Winona: Naa Kordai ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual ...